Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)

被引：7
|
作者：
Loibl, S. [1 ]
Loirat, D. [2 ,3 ]
Tolaney, S. M. [4 ]
Punie, K. [5 ,6 ]
Oliveira, M. [7 ,8 ,9 ]
Rugo, H. S. [10 ]
Bardia, A. [11 ]
Hurvitz, S. A. [12 ]
Brufsky, A. [13 ,14 ]
Kalinsky, K. [15 ]
Cortes, J. [16 ]
O'Shaughnessy, J. [17 ]
Dieras, V. C. [18 ]
Carey, L. A. [19 ]
Gianni, L. [20 ]
Gharaibeh, M. [21 ]
Moore, L. [21 ]
Shi, L. [22 ]
Piccart, M. [23 ,24 ]
机构：
[1] Hamatol Onkol Gemeinschaftspraxis Bethanien Krank, Dept Med & Res, Frankfurt, Germany
[2] Inst Curie, Med Oncol Dept, Paris, France
[3] Inst Curie, D3i, Paris, France
[4] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[5] Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium
[6] Univ Hosp Leuven, Leuven Canc Inst, Multidisciplinary Breast Ctr, Leuven, Belgium
[7] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain
[8] Vall dHebron Univ Hosp, Breast Canc Grp, Barcelona, Spain
[9] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[10] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[11] Harvard Med Sch, Dept Hematol & Oncol, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
[12] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Med Oncol,Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
[13] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Div Hematol Oncol, Pittsburgh, PA 15213 USA
[14] Univ Pittsburgh, Hillman Canc Ctr, Med Ctr, Pittsburgh, PA USA
[15] Columbia Univ Irving Med Ctr, Dept Med, New York, NY USA
[16] Quiron Grp, Med Oncol Dept, Int Breast Canc Ctr, Barcelona, Spain
[17] Texas Oncol Baylor A Charles Sammons Canc Ctr, Med Oncol, Dallas, TX USA
[18] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[19] Univ N Carolina, Med Hematol Oncol Div, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[20] Gianni Bonadonna Fdn, Med Oncol, Milan, Italy
[21] Gilead Sci Inc, Dept Global Value & Access, Morris Plains, NJ USA
[22] Evidera PPD, Dept Evidence Synth Modeling & Commun EMC, Waltham, MA USA
[23] Inst Jules Bordet, Med Oncol Dept, Brussels, Belgium
[24] Univ Libre Bruxelles, Brussels, Belgium
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.540
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
257P
引用
收藏
页码：S472 / S473
页数：2
相关论文
共 50 条
  • [21] Sacituzumab Govitecan for treating Patients with metastatic triple-negative Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (12) : 1271 - 1271
  • [22] ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
    Bardia, A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Rugo, H. S.
    Brufsky, A.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V. C.
    Carey, L. A.
    Gianni, L.
    Piccart, M.
    Loibl, S.
    Goldenberg, D.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1149 - S1150
  • [23] Assessment of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).
    O'Shaughnessy, Joyce
    Punie, Kevin
    Oliveira, Mafalda
    Lynce, Filipa
    Tolaney, Sara M.
    Dalenc, Florence
    Sharma, Priyanka
    Tsai, Michaela L.
    Bardia, Aditya
    Cortes, Javier
    Danso, Michael A.
    Henry, Stephanie
    Perez, Alejandra T.
    Hurvitz, Sara A.
    Kalinsky, Kevin
    Hong, Quan
    Sebastian Olivo, Martin
    Itri, Loretta
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    Joyce O’Shaughnessy
    Adam Brufsky
    Hope S. Rugo
    Sara M. Tolaney
    Kevin Punie
    Sagar Sardesai
    Erika Hamilton
    Delphine Loirat
    Tiffany Traina
    Roberto Leon-Ferre
    Sara A. Hurvitz
    Kevin Kalinsky
    Aditya Bardia
    Stephanie Henry
    Ingrid Mayer
    Yanni Zhu
    See Phan
    Javier Cortés
    Breast Cancer Research and Treatment, 2022, 195 : 127 - 139
  • [25] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    O'Shaughnessy, Joyce
    Brufsky, Adam
    Rugo, Hope S.
    Tolaney, Sara M.
    Punie, Kevin
    Sardesai, Sagar
    Hamilton, Erika
    Loirat, Delphine
    Traina, Tiffany
    Leon-Ferre, Roberto
    Hurvitz, Sara A.
    Kalinsky, Kevin
    Bardia, Aditya
    Henry, Stephanie
    Mayer, Ingrid
    Zhu, Yanni
    Phan, See
    Cortes, Javier
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (02) : 127 - 139
  • [26] Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
    Rugo, Hope S.
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Bardia, Aditya
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Cortes, Javier
    Dieras, Veronique
    Carey, Lisa A.
    Gianni, Luca
    Piccart, Martine J.
    Loibl, Sibylle
    Goldenberg, David M.
    Hong, Quan
    Olivo, Martin
    Itri, Loretta M.
    Kalinsky, Kevin
    NPJ BREAST CANCER, 2022, 8 (01)
  • [27] Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)
    O'Shaughnessy, J.
    Brufsky, A.
    Rugo, H. S.
    Tolaney, S. M.
    Diab, S.
    Punie, K.
    Sardesai, S.
    Hamilton, E.
    Loirat, D.
    Traina, T. A.
    Leon-Ferre, R.
    Hurvitz, S. A.
    Kalinsky, K.
    Bardia, A.
    Henry, S.
    Mayer, I.
    Hong, Q.
    Phan, S.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S473 - S474
  • [28] Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
    Lisa A. Carey
    Delphine Loirat
    Kevin Punie
    Aditya Bardia
    Véronique Diéras
    Florence Dalenc
    Jennifer R. Diamond
    Christel Fontaine
    Grace Wang
    Hope S. Rugo
    Sara A. Hurvitz
    Kevin Kalinsky
    Joyce O’Shaughnessy
    Sibylle Loibl
    Luca Gianni
    Martine Piccart
    Yanni Zhu
    Rosemary Delaney
    See Phan
    Javier Cortés
    npj Breast Cancer, 8
  • [29] Efficacy of Sacituzumab Govitecan (SG) in Patients with metastatic triple negative Breast Cancer (mTNBC) by HER2 Immunohistochemistry (IHC) Status: Results from the Phase 3 ASCENT Study
    Hegewisch-Becker, S.
    Hurvitz, S. A.
    Bardia, A.
    Punie, K.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Carey, L. A.
    Rugo, H. S.
    Yoon, O. K.
    Pan, Y.
    Delaney, R.
    Hofsess, S.
    Hodgkins, P.
    Phan, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 104 - 105
  • [30] Biomarker Evaluation in the Phase 3 ASCENT Study of Sacituzumab Govitecan vs Chemotherapy in Patients With Metastatic Triple-Negative Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 6 - 7
12345